The Company is developing a pipeline of candidates focused on small molecules and biologics that can treat central nervous system (CNS) and immunology disorders. Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) lead candidate for CNS is TNX-102 SL (sublingual formulation of cyclobenzaprine), a non-opioid, centrally-acting analgesic...
BioXcel Therapeutics (NASDAQ: BTAI) is buoyed by the positive results from a Phase 1b clinical trial, to test the efficacy of BXCL501, its lead drug candidate for the treatment of agitation in patients suffering from Schizophrenia. The drug candidate was granted a fast track designation...
Metastatic brain tumor, also known as secondary cancer, is the most common brain tumor in adults and is estimated to affect between 200,000 and 300,000 people per year, according to The American Brain Tumor Association. The growth in the metastatic cancers market is owing to improved diagnostics, increasing...
